


Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley L. Cohan, Harold Moses, Jonathan Calkwood, Carlo Tornatore, Chris LaGanke, Kyle E. Smoot, Venkata Meka, Macaulay Okwuokenye, Christophe Hotermans, Jason P. Mendoza, Monica K. Mann, Leslie A. Meltzer



PII: S2211-0348(18)30081-6
DOI: <https://doi.org/10.1016/j.msard.2018.02.028>
Reference: MSARD791

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 1 September 2017
Revised date: 22 February 2018
Accepted date: 23 February 2018

Cite this article as: Stanley L. Cohan, Harold Moses, Jonathan Calkwood, Carlo Tornatore, Chris LaGanke, Kyle E. Smoot, Venkata Meka, Macaulay Okwuokenye, Christophe Hotermans, Jason P. Mendoza, Monica K. Mann and Leslie A. Meltzer, Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY), *Multiple Sclerosis and Related Disorders*, <https://doi.org/10.1016/j.msard.2018.02.028>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley L. Cohan^a, Harold Moses^b, Jonathan Calkwood^c, Carlo Tornatore^d, Chris LaGanke^e, Kyle E. Smoot^a, Venkata Meka^{f,1}, Macaulay Okwuokenye^f, Christophe Hotermans^f, Jason P. Mendoza^{f,*}, Monica K. Mann^f, Leslie A. Meltzer^{f,2}

^a Providence Multiple Sclerosis Center, 9427, and Providence Brain and Spine Institute, 9135 SW Barnes Road, Suite 461, Providence Health & Services, Portland, OR 97225, USA;

^b Vanderbilt-Ingram Cancer Center, 691 Preston Building, Nashville, TN 37232, USA

^c Schapiro Center for Multiple Sclerosis, Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422, USA;

^d Department of Neurology, Medstar Georgetown University Hospital, Pasquerilla Healthcare Center (PHC), 7th Floor, 3800 Reservoir Road, N.W., Washington, DC 20007, USA

^e North Central Neurology Associates, 1809 Kress St., Cullman, AL 35058, USA

^f Biogen, 225 Binney St., Cambridge, MA 02142, USA

* Correspondence to: Jason P. Mendoza, PhD, Biogen, 225 Binney St., Cambridge, MA 02142, USA; tel: +1 781 464 1706

stanley.cohan@providence.org (S.L. Cohan),

¹ V. Meka performed the majority of the work while an employee of Biogen, Cambridge, MA, USA. V. Meka's current affiliation is with AstraZeneca, 35 Gatehouse Lane, Waltham, MA 02451, USA

² L.A. Meltzer performed the majority of the work while an employee of Biogen, Cambridge, MA, USA. L.A. Meltzer's current affiliation is with Keryx Biopharmaceuticals, 1 Marina Park Drive, Twelfth Floor, Boston, MA 02210, USA

Download English Version:

<https://daneshyari.com/en/article/8647371>

Download Persian Version:

<https://daneshyari.com/article/8647371>

[Daneshyari.com](https://daneshyari.com)